This is a phase II, randomized, double-blind, trial for the use of Rucaparib as maintenance therapy in metastatic and recurrent endometrial cancer.
Females aged 18-89 with primary stage III/IV or recurrent endometrial cancer whom have received at least one prior chemotherapy regimen and no more than two prior cytoxic regimens (including hormonal therapy).
Fox Chase Cancer Center
University of Colorado Hospital
University of Pennsylvania
University of Pittsburgh Cancer Institute
Bradley Corr, MD
Protocol Number: 18-0567
More information available at ClinicalTrials.gov: NCT03617679
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers